News & Updates

Product Highlight - Paracetamol + Orphenadrine Citrate (Norpriexia/Norpriexia Forte)

Film-Coated Tablet 50 mg/35 mg, Forte Tablet 650 mg/35 mg

Product Highlight - Apixaban (Embolis 2.5/Embolis 5)

Film-Coated Tablet 2.5 mg and 5 mg

Product Highlight - Diosmin + Hesperidin (Varicure)

Film-Coated Tablet 450 mg/50 mg

Product Highlight - Tiotropium Bromide (Aviar)

DPI 18 mcg 

Product Highlight - Methylprednisolone (Mepresone)

Tablet 4 mg and 16 mg

Product Highlight - Levodropropizine (Extusiv)

Syrup 30 mg/5 mL

Product Highlight - Telmisartan, Amlodipine Besilate (Mistacor AM)

Tablet 40 mg/5 mg, 40 mg/10 mg, 80 mg/5 mg and 80 mg/10 mg

Product Highlight - Hydrocortisone Sodium Succinate (Ivcort)

Powder for Injection 100 mg

Product Highlight - Cefepime Hydrochloride (Cepiram)

Powder for Injection (vial) 1 g

Hypertension, Telmisartan and Clinical Practice Guidelines in the Philippines: Upholding International Standards in Local Practice

Hypertension in the Philippine Setting

While the Expanded National Nutrition Survey (NNS) conducted by the Food and Nutrition Research Institute (FNRI) using cross-sectional questionnaire and a single-visit BP measurement has shown a significant decline in the prevalence of hypertension from 23.9% in 2013 to 19.2% in 2018, hypertension continues to impose a significant healthcare and socio-economic burden in the Philippines.¹

While it is acknowledged to be the most important modifiable risk factor for disability adjusted life-years worldwide, hypertension awareness in the Philippines is at 67.8% with only 75% of those who are aware receive treatment. Of those under treatment, only 27% have it under control.¹